http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022255248-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a3535b42d1b0f3604161ad7078214ad5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_08c9253f468ce2599099100f97be27b1 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2022-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0838483956a44a4b498da7032d334b27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c999ed7c794643669990f25abf2b5c5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f1f087d52a921719ad1b7689cd20ee6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a780a62512e8c94d172bb9e83acfb3ba |
| publicationDate | 2022-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022255248-A1 |
| titleOfInvention | Therapy using combination of anti-cd26 antibody and immune checkpoint inhibitor |
| abstract | The purpose of the present disclosure is to develop a new combination therapy that exerts a superior antitumor effect as compared to administration of an anti-CD26 antibody alone. In order to assess both the function of an immune checkpoint inhibitor and the antitumor effect of an anti-CD26 antibody, it is necessary to be provided with both a binding site on a human CD26 molecule and an immune system of the same lineage of a cancer cell. Thus, in order to acquire data of an immune checkpoint inhibitor and an anti-CD26 antibody, it is essential to perform analysis in a human immune system and a human tumor cell line. The present inventors have made an attempt to produce a human immune system mouse to be used as a model animal for confirming the effect of the combination between ICI and an anti-CD26 antibody, and have successfully produced a model mouse superior for generating human T-cells. Next, the present inventors have studied the effect of combining an immune checkpoint inhibitor and an anti-CD26 antibody in a tumor bearing model by using said mouse. As a result, it was found that an agent using said combination has a synergistic effect that is stronger than when the respective agents are used individually. |
| priorityDate | 2021-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 159.